Transcriptional profiling reveals that several common fragile-site genes are downregulated in ovarian cancer

Stacy R. Denison, Nicole A. Becker, Matthew J. Ferber, Leslie A. Phillips, Kimberly R. Kalli, John Lee, Jim Lillie, David I. Smith, Viji Shridhar

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Previous transcriptional profiling analysis of 14 primary ovarian tumors identified approximately 12,000 genes as decreased in expression by at least twofold in one or more of the tumors sampled. Among those genes were several known to be mapped to common fragile sites (CFSs), some of which had previously been shown to exhibit a loss of expression in ovarian carcinoma. Therefore, we selected a subset of genes to determine whether they localized within CFSs. Of the 262 genes that were downregulated at least twofold in 13 of 14 tumors, 10 genes were selected based on the following criteria: localization to a CFS band; documented aberrations in at least one malignancy; and feasibility of scoring breakage at the specific CFS. Fluorescence in situ hybridization analysis was performed using bacterial artificial chromosome clones encompassing portions of the genes to determine the position of the genes relative to their corresponding CFSs. Nine genes were determined to localize within seven previously uncloned CFSs. Semiquantitative reverse-transcription/polymerase chain reaction analysis of the cell lines and primary ovarian tumors validated the downregulation of seven of the 10 genes. We identified portions of seven uncloned CFSs and provide data to suggest that several of the genes mapping within CFSs may be inactivated in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)406-415
Number of pages10
JournalGenes Chromosomes and Cancer
Volume34
Issue number4
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'Transcriptional profiling reveals that several common fragile-site genes are downregulated in ovarian cancer'. Together they form a unique fingerprint.

Cite this